Printer Friendly

VIRULIZIN INCREASES SURVIVAL RATE IN ADVANCED MALIGNANT MELANOMA PATIENTS

 TORONTO, April 15 /PRNewswire/ -- Updated results of a multi-center Phase II clinical trial testing the effect of IMUTEC Corporation's VIRULIZIN(TM) in patients with advanced malignant melanoma demonstrated, at the time of reporting, a one-year survival rate of 39 percent for patients treated with VIRULIZIN, compared with 11 percent one-year historical survival for similarly advanced malignant melanoma patients. The interim results of the trial were presented today in Houston, Texas at the Baylor College of Medicine Research Symposium.
 The trial with 33 patients at three hospitals in Mexico is being coordinated by Dr. Jaime de la Garza Salazar, director of research and post graduate studies and president of the scientific committee at the National Cancer Institute, Mexico. Preliminary results of the trial were earlier preseurally derived biopharmaceutical and the leading application of IMUTEC's proprietary technology, has been shown to cause no significant toxicity and only mild transient adverse side effects.
 All patients participating in the trial were diagnosed with advanced (stage III and IV) malignant melanoma. Sixty-four percent of these patients had previously been treated with other therapies, and 82 percent of the patients had more than one metastatic site.
 Among the other findings of the trial investigator:
 -- Patients with two tumor sites had a 49 percent one-year survival rate, compared with a 13 percent one-year survival rate from historical data of similar patients.
 -- Patients with three or more tumor sites had a 31 percent one-year survival rate, compared with a 0 percent one-year survival rate from historical data of similar patients.
 -- Median survival for the 33 patients in the trial was 315 days, compared with a median of 89 days for patients with similarly advanced malignant melanoma. For patients with three or more tumor sites, median survival was 205 days -- versus 60 days for patients with similarly advanced malignant melanoma.
 Trial results also showed quality of life benefits with some patients -- including pain reduction, weight gain and tumor reduction.
 Nineteen patients experienced no tumor growth for periods ranging from 60 to 170 days, with a median of 77 days.
 "We regard these results as an encouraging step in our progress toward commercial development of VIRULIZIN," said Richard A. Potts, IMUTEC president. "This is particularly true given the significant side effects of standard treatments for advanced malignant melanoma."
 IMUTEC is a biotechnology company using its proprietary technology to develop and commercialize naturally derived immunologic biopharmaceuticals for use in the treatment of disease. To date, IMUTEC has applied its technology to produce VIRULIZIN, a potential new drug for the treatment of cancer. VIRULIZIN is currently undergoing Phase II clinical trials at ten North American medical centers.
 IMUTEC's common shares are listed on both NASDAQ and the Canadian Dealer Network System.
 -0- 4/15/93
 /CONTACT: David W. Cooke, director of corporate development of IMUTEC, 416-724-1100, or 800-561-9400, or fax, 416-724-1167, or voice mail ext. 227/
 (IMUT. IMUTF)


CO: IMUTEC Corporation ST: Ontario IN: MTC SU:

PS -- NY065 -- 6258 04/15/93 12:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1993
Words:493
Previous Article:ISTEC EXTENDS EXPIRATION OF WARRANTS
Next Article:PROMEGA CORP. CHALLENGES KEY PATENT HELD BY HOFFMANN-LA ROCHE
Topics:


Related Articles
IMUTEC CORPORATION PHASE II STUDY OF VIRULIZIN IN PATIENTS WITH PANCREATIC CANCER RELEASED
SCIENTIFIC DEVELOPMENTS ADD TO VIRULIZIN KNOWLEDGE BASE
IMUTEC REPORTS FIRST QUARTER RESULTS
PHASE II CLINICAL TRIAL RESULTS RELEASED - VIRULIZIN PROVIDES BENEFITS TO ADVANCED MALIGNANT MELANOMA PATIENTS
IMUTEC PURSUES PROGRAM OF PHASE III CLINICAL TRIALS
STUDY DEFINES MOST-EFFECTIVE TREATMENT FOR CANCER PATIENTS
ATTENTION BUSINESS/NEWS/HEALTH EDITORS:
Melanoma predictive test. (New tests).
Lorus and Mayne Pharma confirm distribution agreement in Brazil.
Lorus Therapeutics allowed United States Patent to protect lead anticancer drug, Virulizin(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters